

Jeffrey C. Raum,^{1,2} Scott A. Soleimanpour,³ David N. Groff,^{1,2} Nathalie Coré,⁴ Laurent Fasano,⁴ Alistair N. Garratt,⁵ Chunhua Dai,⁶ Alvin C. Powers,^{6,7,8} and Doris A. Stoffers^{1,2}



Tshz1 Regulates Pancreatic β -Cell Maturation

Diabetes 2015;64:2905–2914 | DOI: 10.2337/db14-1443

The homeodomain transcription factor Pdx1 controls pancreas organogenesis, specification of endocrine pancreas progenitors, and the postnatal growth and function of pancreatic β -cells. Pdx1 expression in human-derived stem cells is used as a marker for induced pancreatic precursor cells. Unfortunately, the differentiation efficiency of human pancreatic progenitors into functional β -cells is poor. In order to gain insight into the genes that Pdx1 regulates during differentiation, we performed Pdx1 chromatin immunoprecipitation followed by high-throughput sequencing of embryonic day (e) 13.5 and 15.5 mouse pancreata. From this, we identified the transcription factor Teashirt zinc finger 1 (Tshz1) as a direct Pdx1 target. Tshz1 is expressed in developing and adult insulin- and glucagon-positive cells. Endocrine cells are properly specified in Tshz1-null embryos, but critical regulators of β -cell (Pdx1 and Nkx6.1) and α -cell (MafB and Arx) formation and function are downregulated. Adult *Tshz1*^{+/-} mice display glucose intolerance due to defects in glucose-stimulated insulin secretion associated with reduced *Pdx1* and *Clec16a* expression in *Tshz1*^{+/-} islets. Lastly, we demonstrate that *TSHZ1* levels are reduced in human islets of donors with type 2 diabetes. Thus, we position Tshz1 in the transcriptional network of maturing β -cells and suggest that its dysregulation could contribute to the islet phenotype of human type 2 diabetes.

A reduction in functional β -cell mass underlies the progression of all forms of diabetes (1–3). The inability of

exogenously administered therapeutics to replicate the finely tuned regulation of insulin secretion by pancreatic β -cells has raised the development of cell replacement strategies to a high priority. To this end, the directed differentiation of embryonic stem cells to insulin-producing β -cells and the reprogramming of differentiated non- β -cells are being aggressively pursued. The efficiency of generating mature functioning β -cells from human stem cell-derived pancreatic progenitors is low, however, paralleling a relative paucity of knowledge about factors regulating the maturation of hormone-producing cells in the pancreas (4).

Pancreatic and duodenal homeobox 1 (Pdx1) is a critical regulator of pancreas formation and adult β -cell function (5–7). Pdx1 is first expressed in the mouse at embryonic day (e) 8.5 in the prepancreatic endoderm, is maintained in multipotent progenitor cells, and becomes restricted to the β - and δ -cells in the adult islet, with low levels detected in acinar tissue. Developmentally, Pdx1 is critical for maintaining pancreatic progenitors, promotion of endocrine cell specification, and β -cell proliferation (7–10). In the mature β -cell, Pdx1 is required for maintenance of the β -cell phenotype, glucose-stimulated insulin secretion, and cell survival (6,11,12). Human mutations of PDX1 cause pancreatic agenesis and monogenic forms of early- and late-onset diabetes, including neonatal diabetes, maturity-onset diabetes of the young, and late-onset type 2 diabetes (13–17). As it is such a critical regulator of pancreatic development and adult function, protocols aimed

¹Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

²Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

³Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI

⁴Institut de Biologie du Développement de Marseille, UMR 7288, Aix-Marseille Université, CNRS, Marseille, France

⁵Institute of Cell Biology and Neurobiology, Center for Anatomy, Charité University Hospital Berlin, Berlin, Germany

⁶Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

⁷Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN

⁸VA Tennessee Valley Healthcare System, Nashville, TN

Corresponding author: Doris A. Stoffers, stoffers@mail.med.upenn.edu.

Received 18 September 2014 and accepted 8 April 2015.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1443/-/DC1>.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

at differentiating embryonic stem cells to insulin-positive β -cells have relied on Pdx1 as a marker of proper cell differentiation.

We hypothesized that identification of Pdx1 transcriptional targets around the time of the secondary transition, when the principle wave of insulin⁺ cells is formed during embryogenesis, would lead to the discovery of novel maturation factors. To that end, we performed Pdx1 chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-Seq), which led to the identification of the transcriptional regulator Tshz1, a member of the Teashirt zinc finger family of transcription factors that regulate cellular proliferation and differentiation and stem cell maintenance during embryonic development in *Drosophila* (18–21). In mammals, disruption of Tshz1 results in defects in axial skeletal, ear, and palate formation (22) as well as neuronal development and function of the olfactory bulb (23). Here, we demonstrate that Tshz1 is a direct target of Pdx1 in the endocrine pancreas, and we define the role of Tshz1 in β -cell differentiation and adult function utilizing Tshz1 null embryos and Tshz1^{+/-} adult animals. Lastly, we identified Tshz1 as a component of the β -cell transcriptional network whose expression is altered in human islets isolated from donors with type 2 diabetes.

RESEARCH DESIGN AND METHODS

Animals

Animals were housed at the animal care facility at the University of Pennsylvania, and all procedures were approved by the Institutional Animal Care and Use Committee. The Tshz1^{tm1Coré}, Tshz1^{GFP}, Pdx1^{loxP}, and Tg(Neurog3-cre)C1Able alleles have previously been described (5,22–24). All animals were kept on a mixed CD1 \times 129/Sv background. For embryonic experiments, noon of the day of vaginal plug discovery was designated e0.5.

Animal Physiology

Glucose tolerance, insulin tolerance, and in vivo glucose-stimulated insulin secretion tests were performed on 11- to 14-week-old female animals. For glucose tolerance tests, mice were fasted for 16 h before injection of a 2 g/kg body wt 20% D-glucose i.p. Blood glucose was measured by handheld glucometer (FreeStyle/OneTouch) at 0, 15, 30, 60, and 120 min after injection. Serum was collected and circulating insulin was assayed by ELISA (Chemicon). For insulin tolerance tests, mice were fasted for 6 h prior to an injection of 1.5 units/kg insulin i.p. Radioimmunoassay was used to assess total pancreatic insulin and glucagon content from acid-ethanol extracted embryonic and adult pancreata. Samples were quantified by the Radioimmunoassay and Biomarkers Core of the University of Pennsylvania Diabetes Research Center.

Islet Isolation and Proinsulin:Insulin Measurement

Islets were isolated from 11- to 14-week-old female mice by collagenase digestion followed by three rounds of handpicking. Proinsulin and insulin content from isolated adult islets were assessed by ELISA (Chemicon).

ChIP Assays and Library Preparation

Embryonic pancreata from e13.5 ($n = 90$) and e15.5 ($n = 15$) CD1 mice were isolated fixed in 1% formaldehyde and quenched in 150 mmol/L glycine. Pancreata were washed with PBS and lysed in 100 μ L cold lysis buffer (10 mmol/L Tris-HCl at pH 8.0, 10 mmol/L NaCl, 3 mmol/L MgCl₂, 1% NP-40, 0.1% SDS, and 0.5% deoxycholic acid) with protease and phosphatase inhibitors (Calbiochem) for 10 min. Lysates were then sonicated with a Diagenode Bioruptor (30-s on/off pulses for a total of 15 min). Immunoprecipitations were performed as previously described (25) using a goat anti-Pdx1 antiserum (kindly provided by Chris Wright, Vanderbilt University). ChIP PCR was performed with the following primers: Tshz1 intron F, 5'-AGCTCCACACTATCAGGCCAACTT-3'; R, 5'-CAGG GCTTCAGCAATGGATTAGGT-3'; Alb F, 5'-TGGGAAAAC CATCCTATCAAAA-3'; and Alb R, 5'-CACCTCTTTGTTG TTTCTTCTG-3'. ChIP-Seq libraries were prepared as previously described (26). Sequence alignment and statistical analysis were performed by the Functional Genomics Core at the University of Pennsylvania (<http://fgc.genomics.upenn.edu/>).

RNA Isolation and Quantitative RT-PCR Analysis

Embryonic pancreata from e15.5, e16.5, and e18.5 animals were isolated, stored in RNAlater (Ambion), and homogenized in TRIzol (Invitrogen) using a TissueLyser (QIAGEN). Islets were cultured overnight in islet medium (27) and homogenized in TRIzol (Invitrogen). Embryonic and islet RNA was isolated using the RNeasy Mini Kit (QIAGEN). Mouse islet and embryonic RNA was reverse transcribed using SuperScript III (Invitrogen). Transcript was measured using SYBR Green-based quantitative PCR (Bio-Rad), and values were normalized to HPRT transcript as an internal control. Human islet RNA was prepared and quantified as previously described using TaqMan primers specific for TSHZ1 (Applied Biosystems) (28,29). Values are expressed as fold change compared with wild-type littermate tissues. Primer sequences are included in Supplementary Table 1.

Histology

Embryonic and adult pancreata were isolated, fixed in 4% paraformaldehyde for 2 h at 4°C, and cryoembedded in OCT (Tissue-Tek). Ten-micron sections were cut, blocked in 5% donkey serum in PBS with 1% BSA, and incubated with the following primary antibodies in PBS with 1% BSA overnight at 4°C: guinea pig anti-insulin (1:500; Abcam), rabbit anti-glucagon (1:1,000; Sigma-Aldrich), goat anti-GFP (1:100; Abcam), and mouse Ki67 (1:500; BD Biosciences). Cy2, Cy3, and Cy5 secondary antibodies (Jackson ImmunoResearch Laboratories) were used at a 1:500 dilution. DAPI was used as a nuclear counterstain (Thermo Fisher). Images were captured on an Eclipse E600 epifluorescence microscope (Nikon) with a QIClick digital camera (QImaging). Insulin and glucagon area measurements were calculated using MetaMorph software. Area was quantified from e18.5 embryos every

100 μm and adult pancreata every 250 μm from a minimum of four animals per genotype. β -Cell proliferation was quantified on sections from e18.5 embryos every 100 μm with at least 2,000 total β -cells counted per mouse.

Statistics

Data are presented as means \pm SEM. Differences between groups were analyzed using a two-tailed Student *t* test. Values were considered significant when the *P* values were less than 0.05. Two-way ANOVA was performed on glucose and insulin tolerance test data.

RESULTS

Pdx1 Regulates Tshz1 During Mouse Development

In order to identify new regulators of pancreatic endocrine maturation, we performed Pdx1 ChIP-Seq on whole pancreata at e13.5 and e15.5. These time points were chosen as Pdx1 switches from regulating genes involved in multipotency to that of the β -cell program during this time (8,30). We focused on Pdx1 targets that were occupied at both time points and are transcription factors not previously associated with endocrine cell function. From this analysis, we identified *Tshz1*. Pdx1 occupies *Tshz1* at the proximal promoter and two intronic sites 3' of the first exon (Fig. 1A). In order to validate the ChIP-Seq results, we performed Pdx1 ChIP on e15.5 pancreata and performed quantitative PCR using primers spanning the first intronic site, which is highly evolutionarily

conserved and occupied by multiple islet factors including PDX1 in adult human β -cells (31). From this, we confirmed that Pdx1 does occupy this site at e15.5 (Fig. 1B). *Tshz1* transcript is detected in neurogenin (*Ngn3*)-expressing pancreatic endocrine progenitors (32). To determine whether Pdx1 directly regulates *Tshz1* in committed endocrine cells, we performed a loss-of-function experiment by deleting *Pdx1* in endocrine precursors using the *Tg(Neurog3-cre)C1Able* line. *Pdx1* was efficiently deleted from total pancreas RNA at e16.5 (Fig. 1C). Although *Ngn3* expression was not altered, suggesting that the endocrine progenitors are still present, *Tshz1* was markedly downregulated (Fig. 1C). These results demonstrate that Pdx1 regulates *Tshz1* specifically in the endocrine compartment of the pancreas.

Tshz1 Is Expressed in Committed Endocrine Cells of the Developing Pancreas

We next sought to determine the expression pattern of *Tshz1* beginning at the time of the secondary transition and through adulthood. To detect *Tshz1*, we utilized a GFP knock-in allele, which has been shown to faithfully recapitulate *Tshz1* expression during olfactory bulb neuronal development (23). As *Tshz1* mRNA was identified previously in *Ngn3*⁺ cells (32), we first determined whether *Tshz1* is expressed in these cells. Interestingly, *Tshz1* was not coexpressed with *Ngn3*. Rather, *Tshz1* expression was tightly associated with that of the general




Figure 1—Pdx1 regulates *Tshz1* during mouse pancreatic development. **A**: Pdx1 ChIP-Seq of e13.5 and e15.5 whole pancreas. For each time point, the input sample is on top, while the bars underneath each plot represent statistically significant peaks as assessed by HOMER (Hypergeometric Optimization of Motif EnRichment) (53). The red square demarcates the Pdx1 peak conserved between our results and those of Pasquali et al. (31). **B**: Pdx1 ChIP of e15.5 pancreata. Quantitative PCR was performed from three independent ChIPs. ***P* < 0.05, Student *t* test. **C**: *Pdx1*, *Ngn3*, and *Tshz1* transcript level in the e16.5 pancreas of *Pdx1*^{loxP/loxP};*Tg(Neurog3-cre)C1Able* compared with control animals (*Pdx1*^{loxP/loxP}). *n* = 4 pancreata/genotype. **P* < 0.05, ***P* < 0.01, Student *t* test.

endocrine cell marker chromogranin A (Fig. 2A). To determine whether Tshz1 remains expressed in all endocrine cell types or becomes restricted to specific endocrine lineages, we assessed GFP colocalization with the endocrine hormones at both e15.5 and e18.5. At e15.5, we detected GFP in both insulin- and glucagon-positive cells; however, expression was higher in insulin-expressing cells than in glucagon-expressing cells (Fig. 2A). This pattern was maintained at e18.5 and in adult islets (Fig. 2B and C). We also noted a low level of GFP expression in somatostatin and pancreatic polypeptide-positive cells at e18.5 (Fig. 2B and C). Thus, Tshz1 expression is initiated after Ngn3 expression is extinguished and becomes relatively enriched in β -cells, with low levels of expression in α -cells, δ -cells, and pancreatic polypeptide cells.

Tshz1 Is Not Required for Endocrine Cell Specification

Utilizing homozygous *Tshz1*^{GFP/GFP} mice, we examined the cell fate of GFP-expressing cells in the absence of Tshz1 function. We found insulin⁺/GFP⁺ and glucagon⁺/GFP⁺ cells in the pancreas of *Tshz1*^{GFP/GFP} mice (Fig. 3A and data not shown), indicating that Tshz1 is not required for endocrine cell specification. To determine whether Tshz1 is required for the expansion of α - or β -cell mass, we assessed relative area occupied by glucagon

and insulin staining in *Tshz1*^{tm1Corè/tm1Corè} mice. No differences were detected, and there was not any effect on β -cell replication (Fig. 3B and Supplementary Fig. 1). These results indicate that in the absence of Tshz1, endocrine cells are formed and do not undergo increased cell proliferation as has been described in olfactory bulbs lacking Tshz1 (23). The absence of an effect on β -cell proliferation in the context of normal β -cell mass suggests that β -cell survival is also not affected by Tshz1 deficiency. Finally, we assessed expression of all hormone transcripts at e18.5; all showed normal levels in *Tshz1*^{tm1Corè/tm1Corè} mice, with the exception of glucagon, which was reduced by $\sim 60\%$ (Fig. 3D). Collectively, we conclude that Tshz1 is an endocrine-specific transcription factor that is not involved in endocrine cell specification or growth during development.

Tshz1 Deficiency Disrupts the Transcriptional Network of the Developing Endocrine Pancreas

We next examined expression of members of the transcriptional network of the developing endocrine pancreas at e15.5 and e18.5. We detected no change in *Ngn3* or of regulators of α - and β -cell formation at e15.5, suggesting normal size of the endocrine progenitor pool and consistent with the absence of Tshz1 expression in Ngn3⁺ cells and with the normal mass of α - and β -cells observed at e18.5. (Figs. 3B and 4A). In contrast, *Pdx1*, *Nkx6.1*, and *MafB*, key regulators of the β -cell differentiation program, were significantly reduced at e18.5, whereas *MafA* was unchanged (33–35) (Fig. 4B). Expression of *Arx*, a transcriptional regulator of the α -cell program, was also moderately reduced (36,37). Collectively, our results position Tshz1 in the transcriptional networks involved in both α - and β -cell differentiation.

Adult Tshz1 Heterozygous Mice Display Defects in Insulin Secretion

To study the role of Tshz1 in postnatal β -cells, we analyzed *Tshz1*^{+tm1Corè} mice with heterozygous Tshz1 gene disruption (22). Tshz1-null mice could not be investigated, as they die soon after birth owing to an inability to feed secondary to defects in palate formation (22). In contrast, *Tshz1*^{+tm1Corè} mice are viable with normal body weight (Supplementary Fig. 2). α - and β -Cell mass were not different between *Tshz1*^{+tm1Corè} and littermate controls (Fig. 5A). To assess a role for Tshz1 in islet function, we examined acute glucose-stimulated insulin secretion. While basal insulin secretion was normal, *Tshz1*^{+tm1Corè} mice exhibited a 50% decrease in glucose-stimulated insulin secretion at 3 min (Fig. 5B). The reduction in insulin secretion was associated with reduced glucose tolerance measured by intraperitoneal glucose tolerance test (Fig. 5C). Insulin sensitivity of *Tshz1*^{+tm1Corè} mice as assessed by insulin tolerance test was normal, indicating that diminished peripheral insulin sensitivity does not contribute to the glucose intolerance of *Tshz1*^{+tm1Corè} mice (Fig. 5D). These results demonstrate a specific role for Tshz1 in maintaining normal glucose homeostasis through the regulation of β -cell function.




Figure 2—Tshz1 is expressed in insulin- and glucagon-positive cells. *Tshz1*^{GFP/+} pancreata were fixed for 2 h in 4% paraformaldehyde. GFP expression was used as a surrogate for Tshz1. e15.5 (A), e18.5 (B), and 7-week-old (adult) (C) animals were examined for coexpression of Tshz1 (GFP) with Ngn3, chromogranin A (ChrA), insulin (Ins), glucagon (Gcg), somatostatin (SS), and pancreatic polypeptide (PP). For highlighting coexpression at e18.5, the bottom panels in B are higher-magnification images of the top panels in B and of pancreatic polypeptide and somatostatin colocalization. The scale bar in A–C is 25 μ m.




Figure 3—Endocrine cells are specified in *Tshz1*^{-/-} embryos. *A*: *Tshz1*^{GFP/GFP} pancreata were analyzed at e18.5 for GFP and insulin (Ins) staining. *B*: Insulin- and glucagon-stained area in e18.5 wild-type or *Tshz1*^{tm1Corè/tm1Corè} pancreata. *n* = 6 per group. *P* = NS by Student *t* test. Transcript levels from wild-type (WT) or *Tshz1*^{tm1Corè/tm1Corè} whole pancreata at e15.5 (*C*) or e18.5 (*D*). *n* = 7–10 per group per time point. **P* < 0.01, Student *t* test. The scale bar in *A* is 20 μ m. PP, pancreatic polypeptide; SMS, somatostatin.

Reduced insulin secretion could be due to defects in insulin expression or processing. Thus, we assessed insulin content, transcript, and proinsulin:insulin ratios from adult *Tshz1*^{+ / tm1Corè} mice, all of which were normal (Supplementary Fig. 3 and Fig. 6A). Similar to the observations during embryonic development, the transcriptional regulators *Pdx1* and *MafB* were both significantly downregulated in adult *Tshz1*^{+ / tm1Corè} islets, whereas *Nkx6.1* was not changed (Fig. 6A). *Pdx1* has been shown to be a critical regulator of genes involved in glucose-stimulated

insulin secretion including *Glut2* and *Tfam* (11,38). To assess whether these targets are changed, as well as *Clec16a*, a regulator of mitophagy (39) and direct target of *Pdx1* (S.A.S., personal communication), we measured transcript from wild-type and *Tshz1*^{+ / tm1Corè} islets. Although we did not detect any significant changes in *Tfam* or *Glut2*, *Clec16a* was significantly downregulated (Fig. 6A). These data demonstrate that, similar to embryonic development, *Tshz1* regulates the transcriptional network of adult islets; the defects in insulin secretion




Figure 4—Key regulators of α - and β -cell differentiation are decreased in *Tshz1*-null mice. Transcript levels from wild-type (WT) or *Tshz1*^{tm1Cor⁶/tm1Cor⁶} whole pancreata at e15.5 (A) or e18.5 (B) were assessed for changes in key islet developmental regulators. $n = 7$ –10 per group per time point. * $P < 0.05$, ** $P < 0.01$, Student t test.

that we observe are potentially due to reduced mitochondrial function rather than to defects in insulin production or processing.

Type 2 Diabetic Islets Have Decreased TSHZ1

Mutations of individual members of the transcriptional network of β -cells have been identified in monogenic forms of early- and late-onset diabetes in humans (40). This may destabilize the transcriptional network of the mature cell as well as impact specific components of the secretion pathway (31). Indeed, islets from donors with type 2 diabetes have a disruption in several key regulators of the adult β -cell (29) whose expression is perturbed in *Tshz1*^{+/-} islets (Fig. 6A). Therefore, we sought to determine whether *TSHZ1* expression itself is affected in human diabetic and control islets. As previously described (29), *PDX1* levels are decreased by ~50% (Fig. 6B). We observed a modest but significant decrease of *TSHZ1* in diabetic versus control samples, suggesting that *Tshz1* is a component of the β -cell transcriptional network whose expression is altered in human type 2 diabetes.

DISCUSSION

Here, we show that the transcription factor *Tshz1* is regulated by *Pdx1* in committed pancreatic endocrine cells and that *Tshz1* is a component of the transcriptional network of developing and mature hormone-producing

cells. Heterozygous loss of *Tshz1* in adult mice leads to decreased secretory function of β -cells and glucose intolerance. Finally, we show that *Tshz1* is a member of the adult β -cell transcriptional network that is disrupted in human type 2 diabetic islets.

The impact of genetic disruption of *Pdx1* and *Tshz1* on the expression of *Tshz1* and *Pdx1*, respectively, in mature β -cells suggests that a positive-feedback loop involving these two factors becomes operative during islet maturation. Our data indicate that *Pdx1* directly regulates *Tshz1* in the developing pancreas and that *Tshz1* directly or indirectly feeds back to regulate *Pdx1*. The similarity between the high level of *Pdx1* expression and the relative enrichment of *Tshz1* in maturing β -cells further supports this concept. Positive-feedback loops have been described for several factors involved in pancreas formation and function (31,41,42). It is hypothesized that perturbations in one of these factors leads to the development of diabetes through downregulation of all members of the loop and their downstream targets (43). The human *TSHZ1* promoter is occupied by *NKX2.2* and *FOXA2* in adult human islets (31), suggesting additional layers of cross-regulation within the transcriptional network of the mature endocrine pancreas.

We found no effect of *Tshz1* gene disruption on insulin gene expression, insulin content, or insulin processing.




Figure 5—*Tshz1*^{+/-} mice are glucose intolerant owing to decreased insulin secretion. **A**: Islet α - and β -cell mass from 12-week-old female wild-type (WT) and *Tshz1*^{+tm1Cor ϵ} mice. $n = 5$ –6 per group. $P = \text{NS}$ as assessed by Student t test. **B**: Acute glucose-stimulated insulin secretion after a glucose bolus was measured from serum at 0 and 3 min postinjection (13-week-old female mice). $n = 16$ –18 per group. * $P < 0.05$. **C**: Intraperitoneal glucose tolerance test

Neither *Glut2* nor *Tfam*, other transcriptional targets of *Pdx1* that contribute to the *Pdx1* deficiency phenotype, was dysregulated in *Tshz1* heterozygous islets (11,38). The role of *Tshz1* in the mature β -cell may be to regulate mitochondrial function, based on the reduction in *Clec16a*, which we recently demonstrated to regulate insulin secretion and mitochondrial turnover by mitophagy in pancreatic β -cells (39). It is not clear whether *Tshz1* directly regulates *Clec16a* or does so only indirectly through its regulation of *Pdx1*. Future studies involving a combination of ChIP-Seq and RNA-Seq will be required to comprehensively identify the direct targets of *Tshz1* that mediate its regulation of mature β -cell function.

Expression analysis of human ES cells during directed differentiation into endocrine cells describes a pattern of *TSHZ1* expression similar to the pattern we demonstrate here during mouse pancreas development (44). *TSHZ1* is detected just after the specification of the endocrine network, as shown by *NGN3* expression. Furthermore, cells that fail to differentiate into monohormonal cells have decreased levels of *TSHZ1* compared with adult human islets. Thus, increasing *TSHZ1* levels might be an attractive way to promote endocrine cell maturation in current stem cell differentiation protocols in part by promoting optimal expression of key transcription factors.

Our results demonstrate a role for *Tshz1* in regulation of β -cell maturation and not endocrine progenitor survival or expansion. These results are interesting, as studies in *Drosophila* have implicated Teashirt (Tsh) in multiple developmental functions including maintenance of progenitor cells and promotion of differentiation (19,45). These studies suggest that distinct binding partners mediate the disparate functions of Tsh. For example, during *Drosophila* retinal development, complexes including Tsh, Eyeless (Pax6), and Hth (Meis factors) maintain the proliferation of progenitor cells while simultaneously suppressing differentiation (19). Furthermore, conditional knockout of *Tshz1* in the olfactory bulb elicits increased proliferation and a derepression of Pax6, which is not noted in our knockout or heterozygous *Tshz1* animals. The list of cofactors that have been identified to interact with Tsh also includes components of the Hippo pathway, Meis and Pax factors, and members of the Wnt and Hh pathways (19,21,46). These cofactors are noteworthy in that they have been shown to play distinct roles in pancreatic development from progenitor cell maintenance to cell proliferation to endocrine cell function (47–52). Whether *Tshz1* relies on interactions with a known partner to mediate its functional role in endocrine maturation or interacts with a novel cofactor(s) in this context will be

performed on 11-week-old female mice. $n = 10$ –12 per group. $P < 0.05$, *Tshz1*^{+tm1Cor ϵ} versus *Tshz1*^{+/-} mice, by ANOVA. **D**: Insulin tolerance of female mice (11–12 weeks old). $n = 10$ –12 per group. $P = \text{NS}$, *Tshz1*^{+tm1Cor ϵ} versus *Tshz1*^{+/-}, by ANOVA.




Figure 6—Similar transcriptomic profile of adult *Tshz1*^{+/-} islets and human type 2 diabetic (T2D) islets. **A**: Quantitative PCR was performed on isolated islets from 10- to 13-week-old female wild-type (WT) and *Tshz1*^{+tm1Corè} mice. *n* = 6–7 per group. **P* < 0.05 by Student *t* test. **B**: Quantitative PCR was performed on isolated islets that were matched based on their insulin secretion capacity (29). Eight control and eight type 2 diabetic islet preparations were assessed for *PDX1* and *TSHZ1* transcript level. **P* < 0.05, ***P* < 0.01, Student *t* test.

of significant interest and relevance to translational efforts to promote β -cell maturation.

Type 2 diabetes is a complex disease with no single gene identified in its pathogenesis. Perturbations of multiple factors involved in adult function have been demonstrated, which could contribute to the reduced functional capacity of these cells (29). Here, we show that *TSHZ1* is also downregulated in type 2 diabetic islets. The similarity of the transcriptional network of *Tshz1*^{+/-} islets with that of human type 2 diabetic islets highlights the potential importance of *TSHZ1* in human islet function. Collectively, these studies identify *Tshz1* as a new regulator of endocrine cell maturation and function that might be exploited for therapeutic benefit for diabetes.

Acknowledgments. The authors thank the members of the Functional Genomics Core of the University of Pennsylvania Diabetes Center (Diabetes Research Center: P30-DK-19525) for performing sequencing and data analysis and the Radioimmunoassay and Biomarkers Core of the University of Pennsylvania Diabetes Center (P30-DK-19525) for sample processing. The authors also thank Drs. Seung Kim (Stanford University), John Le Lay (University of Pennsylvania), and Catherine Lee May (University of Pennsylvania) for helpful discussions; Dr. Chris Wright (Vanderbilt University) for *Pdx1* antisera; and Dr. Helena Edlund (Umeå University) for the *Pdx1* conditional allele.

Funding. This work was supported by research grants from JDRF and the National Institutes of Health (NIH) (U01-DK-089540 and DK-068157) to D.A.S. J.C.R. was supported in part by NIH F32-DK-089747. S.A.S. was supported by NIH K08-DK-089117. N.C. and L.F. were supported by CNRS, Association pour la

Recherche contre le Cancer (ARC), and grants from Association Française contre les Myopathies (AFM-Téléthon). Funding for A.N.G. was from the German Federal Ministry for Education and Research (BMBF, NGFN-plus, “Alzheimer Disease Integrative Genomics,” PNA-01GS08127-3a). C.D. and A.C.P. were supported by grants from the Department of Veterans Affairs, the NIH (DK-066636, DK-068854, DK-072473, DK-089572, and DK-09538), JDRF, and the Vanderbilt Diabetes Research and Training Center (DK-020593).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. J.C.R. researched data and wrote the manuscript. S.A.S., D.N.G., and C.D. researched data. N.C., L.F., and A.N.G. provided materials and edited the manuscript. A.C.P. contributed to the experimental design and edited the manuscript. D.A.S. supervised the research and wrote the manuscript. D.A.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

- Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* 2003;52:102–110
- Mathis D, Vence L, Benoist C. beta-Cell death during progression to diabetes. *Nature* 2001;414:792–798
- Rhodes CJ. Type 2 diabetes—a matter of beta-cell life and death? *Science* 2005;307:380–384
- Cheng X, Ying L, Lu L, et al. Self-renewing endodermal progenitor lines generated from human pluripotent stem cells. *Cell Stem Cell* 2012;10:371–384
- Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. beta-cell-specific inactivation of the mouse *lpl1/Pdx1* gene results in loss of the beta-cell phenotype and maturity onset diabetes. *Genes Dev* 1998;12:1763–1768
- Gao T, McKenna B, Li C, et al. *Pdx1* maintains β cell identity and function by repressing an α cell program. *Cell Metab* 2014;19:259–271

7. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* 1994;371:606–609
8. Gannon M, Ables ET, Crawford L, et al. PDX-1 function is specifically required in embryonic beta cells to generate appropriate numbers of endocrine cell types and maintain glucose homeostasis. *Dev Biol* 2008;314:406–417
9. Offield MF, Jetton TL, Labosky PA, et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* 1996;122:983–995
10. Oliver-Krasinski JM, Kasner MT, Yang J, et al. The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice. *J Clin Invest* 2009;119:1888–1898
11. Brissova M, Shiota M, Nicholson WE, et al. Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. *J Biol Chem* 2002;277:11225–11232
12. Johnson JD, Ahmed NT, Luciani DS, et al. Increased islet apoptosis in Pdx1+/- mice. *J Clin Invest* 2003;111:1147–1160
13. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. *Nat Genet* 1997;17:138–139
14. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. *Nat Genet* 1997;15:106–110
15. Hani EH, Stoffers DA, Chèvre JC, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. *J Clin Invest* 1999;104:R41–R48
16. Nicolino M, Claiborn KC, Senée V, Boland A, Stoffers DA, Julier C. A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency. *Diabetes* 2010;59:733–740
17. Macfarlane WM, Frayling TM, Ellard S, et al. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. *J Clin Invest* 1999;104:R33–R39
18. Bessa J, Casares F. Restricted teashirt expression confers eye-specific responsiveness to Dpp and Wg signals during eye specification in *Drosophila*. *Development* 2005;132:5011–5020
19. Bessa J, Gebelein B, Pichaud F, Casares F, Mann RS. Combinatorial control of *Drosophila* eye development by eyeless, homothorax, and teashirt. *Genes Dev* 2002;16:2415–2427
20. Denholm B, Hu N, Fauquier T, Caubit X, Fasano L, Skaer H. The tiptop/teashirt genes regulate cell differentiation and renal physiology in *Drosophila*. *Development* 2013;140:1100–1110
21. Peng HW, Slatery M, Mann RS. Transcription factor choice in the Hippo signaling pathway: homothorax and yorkie regulation of the microRNA bantam in the progenitor domain of the *Drosophila* eye imaginal disc. *Genes Dev* 2009;23:2307–2319
22. Coré N, Caubit X, Metchat A, Boned A, Djabali M, Fasano L. Tshz1 is required for axial skeleton, soft palate and middle ear development in mice. *Dev Biol* 2007;308:407–420
23. Ragancokova D, Rocca E, Oonk AM, et al. TSHZ1-dependent gene regulation is essential for olfactory bulb development and olfaction. *J Clin Invest* 2014;124:1214–1227
24. Schonhoff SE, Giel-Moloney M, Leiter AB. Neurogenin 3-expressing progenitor cells in the gastrointestinal tract differentiate into both endocrine and non-endocrine cell types. *Dev Biol* 2004;270:443–454
25. Raum JC, Gerrish K, Artner I, et al. FoxA2, Nkx2.2, and PDX-1 regulate islet beta-cell-specific mafA expression through conserved sequences located between base pairs -8118 and -7750 upstream from the transcription start site. *Mol Cell Biol* 2006;26:5735–5743
26. Khoo C, Yang J, Weinrott SA, et al. Research resource: the pdx1 cistrome of pancreatic islets. *Mol Endocrinol* 2012;26:521–533
27. Raum JC, Hunter CS, Artner I, et al. Islet beta-cell-specific MafA transcription requires the 5'-flanking conserved region 3 control domain. *Mol Cell Biol* 2010;30:4234–4244
28. Dai C, Brissova M, Hang Y, et al. Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets. *Diabetologia* 2012;55:707–718
29. Guo S, Dai C, Guo M, et al. Inactivation of specific β cell transcription factors in type 2 diabetes. *J Clin Invest* 2013;123:3305–3316
30. Pan FC, Wright C. Pancreas organogenesis: from bud to plexus to gland. *Dev Dyn* 2011;240:530–565
31. Pasquali L, Gaulton KJ, Rodríguez-Seguí SA, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. *Nat Genet* 2014;46:136–143
32. White P, May CL, Lamounier RN, Brestelli JE, Kaestner KH. Defining pancreatic endocrine precursors and their descendants. *Diabetes* 2008;57:654–668
33. Fujitani Y, Fujitani S, Boyer DF, et al. Targeted deletion of a cis-regulatory region reveals differential gene dosage requirements for Pdx1 in foregut organ differentiation and pancreas formation. *Genes Dev* 2006;20:253–266
34. Sander M, Sussel L, Connors J, et al. Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas. *Development* 2000;127:5533–5540
35. Schaffer AE, Taylor BL, Benthuyens JR, et al. Nkx6.1 controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity. *PLoS Genet* 2013;9:e1003274
36. Artner I, Blanchi B, Raum JC, et al. MafB is required for islet beta cell maturation. *Proc Natl Acad Sci U S A* 2007;104:3853–3858
37. Collombat P, Mansouri A, Hecksher-Sorensen J, et al. Opposing actions of Arx and Pax4 in endocrine pancreas development. *Genes Dev* 2003;17:2591–2603
38. Gauthier BR, Wiederkehr A, Baqué M, et al. PDX1 deficiency causes mitochondrial dysfunction and defective insulin secretion through TFAM suppression. *Cell Metab* 2009;10:110–118
39. Soleimanpour SA, Gupta A, Bakay M, et al. The diabetes susceptibility gene Clec16a regulates mitophagy. *Cell* 2014;157:1577–1590
40. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. *N Engl J Med* 2001;345:971–980
41. Boj SF, Parrizas M, Maestro MA, Ferrer J. A transcription factor regulatory circuit in differentiated pancreatic cells. *Proc Natl Acad Sci U S A* 2001;98:14481–14486
42. Odom DT, Zizlsperger N, Gordon DB, et al. Control of pancreas and liver gene expression by HNF transcription factors. *Science* 2004;303:1378–1381
43. Ferrer J. A genetic switch in pancreatic beta-cells: implications for differentiation and haploinsufficiency. *Diabetes* 2002;51:2355–2362
44. Xie R, Everett LJ, Lim HW, et al. Dynamic chromatin remodeling mediated by polycomb proteins orchestrates pancreatic differentiation of human embryonic stem cells. *Cell Stem Cell* 2013;12:224–237
45. Datta RR, Weasner BP, Kumar JP. A dissection of the teashirt and tiptop genes reveals a novel mechanism for regulating transcription factor activity. *Dev Biol* 2011;360:391–402
46. Angelats C, Gallet A, Théron P, Fasano L, Kerridge S. Cubitus interruptus acts to specify naked cuticle in the trunk of *Drosophila* embryos. *Dev Biol* 2002;241:132–144
47. Baumgartner BK, Cash G, Hansen H, Ostler S, Murtaugh LC. Distinct requirements for beta-catenin in pancreatic epithelial growth and patterning. *Dev Biol* 2014;391:89–98
48. Gao T, Zhou D, Yang C, et al. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. *Gastroenterology* 2013;144:1543–1553
49. George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE. Hippo signaling regulates pancreas development through inactivation of Yap. *Mol Cell Biol* 2012;32:5116–5128

50. Lau J, Hebrok M. Hedgehog signaling in pancreas epithelium regulates embryonic organ formation and adult beta-cell function. *Diabetes* 2010;59:1211–1221

51. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. *Nature* 1997;386:399–402

52. St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A, Gruss P. Pax6 is required for differentiation of glucagon-producing alpha-cells in mouse pancreas. *Nature* 1997;387:406–409

53. Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* 2010;38:576–589